Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508
- 1 September 1984
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 10 (9), 1749-1753
- https://doi.org/10.1016/0360-3016(84)90542-x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Clinical trials of radiosensitizers: What should we expect?International Journal of Radiation Oncology*Biology*Physics, 1984
- Selection of appropriate studies for phase III trials of radiosensitizersInternational Journal of Radiation Oncology*Biology*Physics, 1983
- Clinical perspectives for the use of new hypoxic cell sensitizersInternational Journal of Radiation Oncology*Biology*Physics, 1982
- The potential benefit from a perfect radiosensitizer and its dependence on reoxygenationThe British Journal of Radiology, 1982
- Initial pharmacology and toxicology of intravenous desmethylmisonidazoleInternational Journal of Radiation Oncology*Biology*Physics, 1982
- Radiosensitization of the RIF-1 murine flank tumor by desmethylmisonidazole (Ro 05 9963) during interstitial brachytherapyInternational Journal of Radiation Oncology*Biology*Physics, 1982
- SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical useInternational Journal of Radiation Oncology*Biology*Physics, 1981
- Neurotoxicity with desmethylmisonidazoleThe British Journal of Radiology, 1981
- Misonidazole in fractionated radiotherapy: are many small fractions best?The British Journal of Radiology, 1980
- Misonidazole—A drug for trial in radiotherapy and oncologyInternational Journal of Radiation Oncology*Biology*Physics, 1979